Two back-to-back genotyping deals last week with Illumina and an Affymetrix service provider show that GlaxoSmithKline is expanding its existing SNP-genotyping service pacts to include more whole-genome genotyping.
Illumina and Affy service provider Expression Analysis announced their separate deals with GSK on Aug. 2. Under the terms of GSK’s agreement with Illumina, the San Diego firm will use its Sentrix HumanHap550 BeadChips for a series of whole-genome association studies for Glaxo.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.